1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with bosentan anhydrous in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Arora, R; Jawad, E | 1 |
| de Boer, MA; Mouchaers, KT; Postmus, PE; Schalij, I; van der Laarse, WJ; van Hinsbergh, VW; van Nieuw Amerongen, GP; Vonk Noordegraaf, A | 1 |
| Caldwell, E; de Frutos, S; Gonzalez Bosc, LV; Kanagy, NL; Nitta, CH; Walker, MK; Wang, J; Wang, W | 1 |
| Huang, XM; Yu, YP | 1 |
| Fukumoto, Y | 1 |
| Chen, D; Chen, Y; Du, G; Fang, L; Niu, Z; Yuan, T; Zhang, H | 1 |
3 review(s) available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and bosentan anhydrous
| Article | Year |
|---|---|
Chronic stable angina pectoris.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetanilides; Angina Pectoris; Antihypertensive Agents; Benzazepines; Bosentan; Chronic Disease; Counterpulsation; Cyclic Nucleotide-Gated Cation Channels; Exercise Test; Heart Murmurs; Humans; Ivabradine; Myocardial Contraction; Myocardial Ischemia; Myocardial Revascularization; Myocardium; Nicorandil; Oxygen Consumption; Perhexiline; Piperazines; Protein Kinase Inhibitors; Ranolazine; Sulfonamides; Trimetazidine; Vasodilator Agents | 2008 |
[Progress in pharmacotherapy of pulmonary arterial hypertension in children].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Bosentan; Calcium Channel Blockers; Child; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Iloprost; Sulfonamides | 2012 |
[Role of the Rho-kinase pathway in pulmonary arterial hypertension].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Bosentan; Drug Therapy, Combination; Epoprostenol; Humans; Hypertension, Pulmonary; Mice; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Rats; rho-Associated Kinases; Signal Transduction; Sildenafil Citrate; Sulfonamides; Sulfones; Vascular Resistance | 2014 |
3 other study(ies) available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and bosentan anhydrous
| Article | Year |
|---|---|
Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Familial Primary Pulmonary Hypertension; Heart Ventricles; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Monocrotaline; Piperazines; Pulmonary Artery; Purines; Rats; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2010 |
NFATc3 contributes to intermittent hypoxia-induced arterial remodeling in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Aorta, Thoracic; Bosentan; Dioxoles; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Genes, Reporter; Hemodynamics; Hyperoxia; Hypertension; Male; Mesenteric Arteries; Mice; Mice, Inbred BALB C; Mice, Knockout; Mice, Transgenic; NFATC Transcription Factors; Promoter Regions, Genetic; Protein Kinase Inhibitors; Receptor, Endothelin A; rho-Associated Kinases; Sulfonamides; Time Factors | 2010 |
DL0805-1, a novel Rho-kinase inhibitor, attenuates lung injury and vasculopathy in a rat model of monocrotaline-induced pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Bosentan; Disease Models, Animal; Hypertension, Pulmonary; Indazoles; Male; Monocrotaline; Nitriles; Protein Kinase Inhibitors; Pulmonary Artery; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; Vasodilator Agents | 2022 |